SCHEMBL25008387

SCHEMBL25008387

O=C1COCCCN1CCCNc1nc(Cl)ncc1C(F)(F)F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ULK1 O75385 1/20 0.44
ULK2 Q8IYT8 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.39
HTT P42858 1/20 0.39
ALDH1A1 P00352 4/20 0.37
KDM4E B2RXH2 3/20 0.37
HSD17B10 Q99714 3/20 0.37
LMNA P02545 2/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
CHEK1 O14757 7/20 0.37
STK17A Q9UEE5 1/20 0.36
FLT3 P36888 6/20 0.36
POLB P06746 1/20 0.35
MAPT P10636 1/20 0.35
MAPK1 P28482 1/20 0.35
GFER P55789 1/20 0.35
PGK1 P00558 1/20 0.35
HPGD P15428 1/20 0.35
MEN1 O00255 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29989339 0.87 SMN1; SMN2 (0.51) ULK1ULK2SMN1; SMN2HTTALDH1A1
SCHEMBL27087788 0.87 SMN1; SMN2 (0.51) ULK1ULK2SMN1; SMN2HTTALDH1A1
SCHEMBL22648377 0.87 ALDH1A1 (0.41) ULK1ULK2SMN1; SMN2HTTALDH1A1
SCHEMBL25008207 0.86 ULK1 (0.40) ULK1ULK2SMN1; SMN2HTTALDH1A1
SCHEMBL25008186 0.86 SMN1; SMN2 (0.48) ULK1ULK2SMN1; SMN2HTTALDH1A1
SCHEMBL22648392 0.86 ULK1 (0.46) ULK1ULK2SMN1; SMN2HTTALDH1A1
SCHEMBL25008208 0.85 ULK1 (0.58) ULK1ULK2SMN1; SMN2HTTALDH1A1
SCHEMBL22648395 0.85 ALDH1A1 (0.38) SMN1; SMN2HTTALDH1A1KDM4EHSD17B10
SCHEMBL22648425 0.84 ULK1 (0.43) ULK1ULK2SMN1; SMN2HTTALDH1A1
SCHEMBL22648266 0.82 TBK1 (0.41) ULK1ULK2SMN1; SMN2ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230039712-A1 PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC 2023-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230039712-A1 PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF BECN1, SQSTM1, ATG7 ULK1 4/4885ULK2 9/4885SMN1; SMN2 3477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.